IBD Treatment

Researchers at McMaster University and MIT have achieved a groundbreaking milestone by discovering a new antibiotic, enterololin, specifically targeting inflammatory bowel diseases (IBD). What makes this discovery even more remarkable is the use of artificial intelligence (AI) to predict the drug’s mechanism of action before traditional methods could validate it. This dual breakthrough not only offers hope for millions suffering from conditions like Crohn’s disease but also highlights the transformative potential of AI in drug discovery.